| Literature DB >> 35529929 |
Ana Myriam Lavín-Pérez1, Daniel Collado-Mateo1, Alejandro Caña-Pino2, Santos Villafaina3,4, Jose Alberto Parraca4,5, María Dolores Apolo-Arenas2.
Abstract
This systematic review aimed to provide an up-to-date analysis of the effects of equine-assisted therapies (EAT) in people with multiple sclerosis (PwMS). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to conduct this systematic review. PubMed and Web of Science databases were employed in the search, which ended in February 2022. The risk of bias analysis was performed using the Evidence Project tool. After removing duplicates, thirty-nine studies were identified. However, only ten fulfilled the inclusion criteria and were included in this systematic review. Therefore, a total of 195 PwMS, aged between 40.3 and 51.3, were included in this systematic review. EAT-based interventions had a mean length of 13.6 weeks with a session´s frequency ranging from ten to once a week. All sessions involved real horses and lasted a mean of 34.4 min. Among the included articles, four were randomized controlled trials (RCT), four did not perform randomization, and two employed a prepost design without a control group. RCTs showed positive effects on quality of life, fatigue, balance, spasticity, and gait speed. Furthermore, non-RCT showed improvements in balance, spasticity, and postural control (postural control was not assessed in RCT studies). Importantly, significant effects were only observed when the comparison group was inactive or followed usual care. Therefore, EAT is a promising and effective therapy to improve quality of life, fatigue, balance, spasticity, and gait speed in PwMS. However, since comparison groups are heterogeneous, results could vary depending on the research design. Moreover, the inclusion of noncontrolled studies (in order to have a wide perspective of the state of art) could increase the risk of bias and make the results be taken with caution.Entities:
Year: 2022 PMID: 35529929 PMCID: PMC9068279 DOI: 10.1155/2022/9656503
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Flow diagram of the study selection.
Characteristics of the participants included in the systematic review.
| Study | Randomization | Group | Sample size (% of females) | Age (SD) | Years from diagnosis (SD) | Disability level (SD) | Body composition data (SD) |
|---|---|---|---|---|---|---|---|
|
| Yes (RCT) | EATG |
| 45.5 (9.7) | 9 (6.1) | EDSS (median): 2 | H: 162 (4.2)/W: 67 (13.1)/BCD: 25.5 |
| ICG |
| 44.8 (8.8) | 8.8 (5.7) | EDSS (median): 1.75 | H: 163 (6.6)/W: 68.7 (13.4)/BCD: 25.9 | ||
|
| No (non-RCT) | EATG |
| 41.3 (3.3) | 15.5 (5) | NR | NR |
| ICG |
| 51.3 (4.6) | 17.5 (7.3) | NR | NR | ||
|
| Yes (RCT) | EATG |
| 50 (median); | 16.5 (median) | EDSS < 5 : 10 EDSS ≥ 5 : 20 | W: 67 (10.3) |
| CG |
| 51 (median); | 17.6 (median) | EDSS < 5 : 11 EDSS ≥ 5 : 26 | W: 70.6 (9.9) | ||
|
| Yes (RCT) | EATG |
| 46.9 (7.6) | 22.3 (8.3) | EDSS: 3.8 (1.1) | H: 167.9 (9.0)/W: 72.5 (12.3)/BCD: 25.7 |
| ACG |
| 44.3 (8.1) | 16.1 (11.3) | EDSS: 3.8 (1.5) | H: 168.2 (8.2)/W: 65.0 (8.9)/BCD: 23.03 | ||
|
| No (non-RCT) | EATG |
| 52.33 (13.28) | 14 (13.89) | 4 (1.32) | NR |
|
| No (non-RCT) | EATG |
| 44 (9.1) | 8.6 (9.6) | NR | H: 162 (1)/W: 68.1 (16.6)/BCD: 25.9 (5.3) |
| ACG |
| 40.3 (15.9) | 8.2 (5.6) | NR | H: 142 (6.2)/W: 72 (34.2)/BCD: 25.2 (25) | ||
|
| No (non-RCT) | EATG |
| 44.8. Range: 34–59 | 8.3 (7) | EDSS: 5.2 (1.2) | NR |
| ACG |
| 46.2. Range: 38–64 | 7.8 (7) | EDSS: 4.9 (1.3) | NR | ||
|
| No (non-RCT) | EATG |
| 42.4 (14.2) | 9.9 (8.2) | NR | NR |
| ICG |
| 47.7 (14.1) | 12.7 (6.6) | NR | NR | ||
|
| No (non-RCT) | EATG |
| 47.9 (8.4) | 10 (7) | 5 (6) | NR |
EATG: equine-assisted therapy group; ICG: control group; NR: not reported; SD: standard deviation; EDSS: Extended Disability Dtatus Scale; H: height (cm); W: weight (kg): BCD: body composition data; R: range; ACG: active control group.
Characteristics of the interventions included in the systematic review.
| Study | Group | Duration | Frequency | Sessions´ duration | Setting | Type of exercise | Exercise description |
|---|---|---|---|---|---|---|---|
| Moraes (2020) and Moraes (2021) | EATG | 8 weeks | 2 days/week | 35 min | Military Police Hippotherapy Center in Brasilia, Brazil | Hippotherapy | Stretching and warming-up exercises on the horse (5 min); EAT (28 min): balance, mobility, and functional exercises. Thirteen progressive tasks were performed (from “serpentine movement throwing hoops on cone” to “short obstacle courses”); calm down (2 min): relaxation with the horse always in motion. |
| ICG | Normal therapeutic routine and participating in the intervention after the follow-up evaluation | ||||||
| Muñoz-Lasa (2019) | EATG | 24 weeks | 1 day/week | From 20 to 40 min | MHG foundation equestrian therapy team | Hippotherapy | NR |
| ICG | NR | ||||||
| Vermöhlen (2017) | EATG | 12 weeks | 1 day/week | 30 min (EAT) | Multicenter (five centers in Germany) | Standard care + horseback riding therapy | Developed following the guidelines for hippotherapy of Deutsches Kuratorium für Therapeutisches Reiten. |
| ICG | Standard care: symptomatic drug treatment, immunotherapy, and physiotherapy | ||||||
| Frevel (2015) | EATG | 12 weeks | 2 days/week | 20–30 min | Hospital with therapeutic riding center “Gut Üttingshof, Bad Mergentheim” | Hippotherapy | EAT: riding forward, backward, side-ways, changes in horse´s speed from slow to moderate, diagonal change of direction, sudden stops and starts. |
| ACG | 12 weeks | 2 days/week | 45 min | Internet-based home training | Balance, postural control, and strength exercises | Balance, postural control, and strength exercises for the main muscle groups of the lower limbs, trunk, and shoulder girdle. 8–15 repetitions. 2–3 sets of moderate intensity (Borg Scale: 11–14). | |
| Lindroth (2015) | EATG | 6 weeks | 2 days/week | 40 min | Adaptive riding center | Hippotherapy | 5-min warm-up with the participant sitting forward on the horse with no stirrups, followed by 30 min of individualized intervention (balance exercises in different positions) and a 5-min cool-down. |
| Menezes (2013) | EATG | 16 weeks | 2 days/week | 50 min | Association of PwMS of Santa Maria, Brazil | Hippotherapy | Stretching and contact with the horse (10 min). |
| ACG | Complementary therapeutic intervention: pilates, swimming, and weightlifting | ||||||
| EATG | 20 weeks on and 4 weeks off in between | 1 day/week | 30–40 min (EAT) | Fundación Caballo Amigo in Villanueva de la Can˜ada (Madrid) | Therapeutic horseback riding and conventional physiotherapy | EAT: exercises based on rider's motor skills, balance, and body posture in a slow steady horse gait (four-beat walk). | |
| Muñoz-Lasa (2011) | ACG | 20 weeks on and 4 weeks off in between | 1 day/week | 40 min | ADEMM in Madrid | Conventional physiotherapy | Aerobic, balance, strength, and flexibility exercises. |
| Silkwood-Sherer (2007) | EATG | 14 weeks | 1 day/week | 40 min | NR | Therapeutic horseback riding | Warm-up (5 min): slow pace (90–100 steps/min) and stretching on the horse, progressively increasing to moderate pace (125–130 steps/min). |
| ICG | NR: no rehabilitation program with the chance of participating in the intervention after the follow-up evaluation | ||||||
| Hammer (2005) | EATG | 11 weeks | 10 sessions/week | 30 min | NR | Therapeutic riding | Trunk rotation exercises, for example, reaching the ears or tail of the horse with one hand, reaching the opposite knee or diagonally, towards the ceiling. The exercises involved balance and driving skills. |
EATG: equine-assisted therapy group; ICG: inactive control group, EAT: equine-assisted therapy; NR: not reported; ACG: active control group; PwMS: people with multiple sclerosis; EDSS: Extended Disability Status Scale.
Effects of equine-assisted therapy intervention on the assessed instrument.
| Study | Tool | Groups | Before intervention | After intervention | Effect size [CI 95%] | Differences ( | Between-group |
|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Within-group | |||||
|
| |||||||
| Moraes (2021) | FAMS (total) | EATG | 133.4 (35.2) | 151.4 (38.3) | 0.11 [−0.57, 0.80]SMD |
|
|
| ICG | 143.2 (27.2) | 138.7 (27.2) |
| ||||
| Muñoz-Lasa (2019) | KHQ | EATG | 34.83 (16.15) | 17.7 (6.95) | 1.38 [ 0.1, 2.6]d |
| NSD |
| ICG | 32.36 (19.99) | 34 (21.73) | −0.08 [−1.5, 1.3]d | NR | |||
| MSQOL-54 (2,3) | EATG | 2.85 (0.9) | 3.55 (0.61) | −0.85 [−2.0, 0.3]d |
| NSD | |
| ICG | 2.63 (1.3) | 2.61 (1.05) | 0.02 [−1.4, 1.4]d | NR | |||
| Vermöhlen (2017) | MSQOL-54 (physical health) | EATG | 46.0 (14.2) | 57.0 (15.1) | 0.36 [−0.12, 0.85]SMD | NR |
|
| ICG | 53.7 (14.6) | 51.3 (15.9) | NR | ||||
| MSQOL-54 (mental health) | EATG | 62.6 (18.0) | 75.7 (15) | 0.64 [0.14, 1.13]SMD | NR |
| |
| ICG | 67.1 (17.2) | 64.2 (19.9) | NR | ||||
| Frevel (2015) | HAQUAMS total | EATG | 13.6 (2.3) | 14.5 (2.1) | 0.38 [−0.62, 1.37]SMD | NSD | NSD |
| ACG | 11.5 (4.1) | 13.0 (4.9) | NSD | ||||
| Hammer (2005) | SF-36 (general health) | EATG | 54.5 (25.82) | 53.8 (19.26) | NA | NA | NA |
| SF-36 (mental health) | EATG | 70 (19.74) | 69.6 (30.53) | NA | NA | NA | |
| SF-36 (physical functioning) | EATG | 40 (24.30) | 37 (20.38) | NA | NA | NA | |
|
| |||||||
|
| |||||||
| Moraes (2021) | FSS | EATG | 5.0 (1.6) | 4.0 (1.7) | −0.17 [−0.86, 0.51]SMD |
|
|
| ICG | 4.5 (1.7) | 4.3 (1.7) |
| ||||
| MFIS Total | EATG | 44.2 (19.0) | 32.3 (18.5) | −0.86 [−1.57, −0.14]SMD |
|
| |
| ICG | 48.1 (10.3) | 45.9 (11.5) |
| ||||
| Muñoz-Lasa (2019) | FIS | EATG | 5.52 (0.67) | 1.93 (0.83) | 4.76 [2.5, 7.0]d |
| NSD |
| ICG | 2.85 (0.48) | 2.87 (0.74) | −0.03 [−1.4, 1.4]d | NR | |||
| Vermöhlen (2017) | FSS (sum score of FSS) | EATG | 51.80 (10.5) | 42.6 (11.4) | −0.38 [−0.86, 0.11]SMD | NR |
|
| ICG | 47.8 (11.9) | 46.8 (10.6) | NR | ||||
| Frevel (2015) | FSS | EATG | 5.40 (0.80) | 4.4 (1) | 0.24 [−0.75, 1.22]SMD |
| NSD |
| ACG | 4.50 (1.90) | 4.00 (2.00) | NSD | ||||
| MFIS | EATG | 44.7 (18.3) | 22.9 (11.8) | −0.31 [−1.30, 0.67]SMD |
| NSD | |
| ACG | 34.6 (22.6) | 28.5 (20.8) | NSD | ||||
|
| |||||||
|
| |||||||
| Vermöhlen (2017) | BBS | EATG | 40.60 (11.50) | 47.0 (8.7) | 0.19 [−0.29, 0.67]SMD | NR |
|
| ICG | 42.10 (10.90) | 45.10 (10.90) | NR | ||||
| Frevel (2015) | BBS | EATG | 40.30 (9.80) | 45.8 (8.3) | −0.08 [−1.06, 0.90]SMD |
| NSD |
| ACG | 43.50 (9.90) | 46.50 (9.00) |
| ||||
| DGI | EATG | 12.8 (6.4) | 15.8 (6.6) | 0.07 [−0.91, 1.05]SMD |
| NSD | |
| ACG | 13.3 (6.6) | 15.3 (6.5) |
| ||||
| Silkwood-Sherer (2007) | BBS | EATG | 39.38 (16.87) | 56 (15.11) | 1.31 [0.04, 2.58]† | NR |
|
| ICG | 41.00 (9.19) | 40.20 (7.91) | NR | ||||
| Lindroth (2015) | BBS | EATG | 42 (1.73) | 46 (0) | NA | NA | NA |
| Hammer (2005) | BBS | EATG | 40.5 (24.57) | 31 (26.06) | NA | NA | NA |
|
| |||||||
|
| |||||||
| Moraes (2021) | Timed up and go test | EATG | 9.9 (3.1) | 7.5 (2.2) | −0.27 [−0.95, 0.42]SMD |
|
|
| ICG | 8.7 (2.5) | 8.09 (2.13) |
| ||||
| Muñoz-Lasa (2011) | POMA | EATG | 16 (6.1) | 19.3 (3.6) | 1.23 [0.38, 2.08]† |
| NSD |
| ACG | 17.3 (6.8) | 17.1 (6.7) | NSD | ||||
| Silkwood-Sherer (2007) | POMA | EATG | 18.44 (6.45) | 22.11 (4.82) | −2.05 [−3.51, −0.59]† | NR |
|
| ICG | 19.33 (3.9) | 18.83 (3.98) | NR | ||||
| Hammer (2005) | Timed up and go test | EATG | 14.85 (7.52) | 14.82 (7.75) | NA | NA | NA |
|
| |||||||
|
| |||||||
| Muñoz-Lasa (2019) | Modified Ashworth Scale | EATG | 1.25 (0.25) | 0.5 (0.55) | 3.40 [1.11, 5.69]† |
|
|
| ICG | 1.12 (0.58) | 0.82 (0.48) | NSD | ||||
| Vermöhlen (2017) | NRS | EATG | 4.6 (2.1) | 3.2 (2.4) | −0.25 [−0.74, 0.23]SMD | NR |
|
| ICG | 4.4 (2.2) | 3.8 (2.3) | NR | ||||
|
| |||||||
|
| |||||||
| Moraes (2020) | Walking endurance (6-minute WT (m)) | EATG | 459.06 (118.34) | 503.59 (126.38) | 0.06 [−0.63, 0.74]SMD |
|
|
| ICG | 513.00 (101.97) | 497.13 (88.88) |
| ||||
| Frevel (2015) | 2-minute WT | EATG | 130.3 (22.5) | 141.3 (28.8) | 0.24 [−0.75, 1.22]SMD | NSD | NSD |
| ACG | 128.6 (50.7) | 130.0 (57.1) | NSD | ||||
|
| |||||||
|
| |||||||
| Moraes (2020) | Speed (cm/s) | EATG | 97.84 (25.94) | 114.93 (31.20) | 0.29 [−0.39, 0.98]SMD |
|
|
| ICG | 110.95 (33.35) | 105.95 (28.61) |
| ||||
| Muñoz-Lasa (2011) | Speed (m/s) | EATG | 0.44 (0.11) | 0.48 (0.10) | −0.38 [−1.2, 0.4]d | NSD | |
| Lindroth (2015) | FGA | EATG | 14 (4.36) | 18 (6.24) | NA | NA | NA |
|
| |||||||
|
| |||||||
| Muñoz-Lasa (2011) | EDSS | EATG | 5.2 (1.2) | 5.2 (1.1) | 0 [−0.8 , 0.8]d | NSD | NSD |
| ACG | 4.9 (1.3) | 5 (1.3) | −0.08 [−0.8, 0.6]d | NSD | |||
|
| |||||||
|
| |||||||
| Vermöhlen (2017) | VAS | EATG | 32.2 (29.9) | 24.9 (27.6) | 0.05 [−0.43, 0.54]SMD |
| NSD |
| ICG | 24.7 (29.3) | 23.4 (27.0) |
| ||||
|
| |||||||
|
| |||||||
| Muñoz-Lasa (2011) | Barthel Index | EATG | 89.6 (10.5) | 90.4 (8.9) | −0.08 [−0.9, 0.7]d | NSD |
|
| ACG | 90.3 (10.9) | 90.7 (11.3) | −0.02 [−0.8, 0.7]d | NSD | |||
|
| |||||||
|
| |||||||
| Moraes (2021) | CoP Speed (cm/s), stable surface, and eyes open | EATG | 1.2 (0.4) | 0.7 (0.4) | −1.21 [−1.96, −0.46]SMD |
|
|
| ICG | 1.4 (0.7) | 1.4 (0.7) |
| ||||
| CoP Speed (cm/s), stable surface, and eyes closed | EATG | 1.6 (0.6) | 1.1 (0.6) | −0.98 [−1.70, −0.25]SMD |
|
| |
| ICG | 2.0 (1.1) | 1.7 (0.6) |
| ||||
| CoP Speed (cm/s), foam surface, and eyes open | EATG | 2.7 (0.9) | 1.6 (0.9) | −0.80 [−1.51, −0.09]SMD |
|
| |
| ICG | 2.8 (1.1) | 2.3 (0.8) |
| ||||
| CoP Speed (cm/s), foam surface, and eyes closed | EATG | 5.9 (2.2) | 2.6 (1.6) | −1.14 [−1.88, −0.40]SMD |
|
| |
| ICG | 6.4 (2.7) | 5.10 (2.6) |
| ||||
|
| |||||||
| Menezes (2013) | AMPap (cm), eyes open | EATG | 2.85 (0.93) | 2.28 (0.68) | 0.70 [−0.4, 1.8]d |
|
|
| ICG | 1.58 (0.35) | 1.89 (0.99) | −0.42 [−1.8 , 1.0]d | ||||
| AMPap (cm), eyes closed | EATG | 3.91 (1.70) | 3.02 (0.84) | 0.66 [−0.4, 1.7]d |
|
| |
| ICG | 2.39 (1.71) | 2.61 (1.37) | −0.14 [−1, 5, 1.2]d | ||||
| AMPml (cm), eyes open | EATG | 2.2 (1.19) | 1.66 (0.76) | 0.54 [−0.5, 1.6]d | NSD |
| |
| ICG | 0.96 (0.43) | 0.96 (0.63) | 0 [−1.4, 1.4]d | ||||
| AMPml (cm), eyes closed | EATG | 3.28 (2.21) | 2.17 (0.99) | 0.65 [−0.4, 1.7]d | NSD |
| |
| ICG | 1.41 (0.67) | 1.08 (0.67) | 0.49 [−0.9, 1.9]d | ||||
| Msap (cm/s), eyes open | EATG | 1.44 (0.56) | 1.48 (0.46) | −0.08 [−1.1, 1.0]d | NSD |
| |
| ICG | 0.83 (0.19) | 0.97 (0.28) | −0.59 [−2.0, 0.8] d | ||||
| Msap (cm/s), eyes closed | EATG | 1.91 (0.79) | 1.85 (0.70) | 0.08 [−1.0, 1.1]d | NSD |
| |
| ICG | 0.99 (0.27) | 1.33 (0.35) | −1.09 [−2.6, 0.4]d | ||||
| MSml (cm/s), eyes open | EATG | 1.30 (0.75) | 1.19 (0.59) | 0.16 [−0.9, 1.2]d |
|
| |
| ICG | 0.62 (0.30) | 0.72 (0.28) | −0.34 [−1.7, 1.1]d | ||||
| MSml (cm/s), eyes closed | EATG | 1.70 (0.99) | 1.19 (0.41) | 0.67 [−0.4, 1.8]d |
|
| |
| ICG | 0.69 (0.26) | 0.84 (0.15) | −0.71 [−2.1, 0.7]d | ||||
|
| |||||||
| Lindroth (2015) | SOT | EATG | 67.33 (9.29) | 73 (12.49) | NA | NA | NA |
SD: standard deviation; EATG: equine-assisted therapy group; ICG: inactive control group; NR: not reported; ACG: active control group; NSD: not significant differences; dwithin group Cohen's d value with an interval confidence of 95%; SMDStandardized Mean Difference results of randomized trials (calculated with after intervention data); †Standardized Mean Difference results of nonrandomized trials (calculated with change from baseline data); NA: not applied; MSQOL-54: Multiple Sclerosis Quality of Life-54; HAQUAMS: Hamburg Quality of Life Questionnaire in Multiple Sclerosis; FAMS: Functional Assessment of Multiple Sclerosis Quality of Life; SF-36: Short Form 36; KHQ: general health perception of King's Health Questionnaire; FSS: Fatigue Severity Scale; MFIS: Modified Fatigue Impact Scale; VAS: Visual Analogue Scale; BBS: Berg Balance Scale; POMA: Performance Oriented Mobility Assessment; NRS: Numeric Rating Scale; WT: walking test; FGA: Functional Gait Assessment; EDSS: Extended Disability Status Scale; CoP: center of pressure; AMPap: amplitude of center of pressure displacement in the antero-posterior directions; AMPml: amplitude of center of pressure displacement in the medial-lateral directions; Msap: mean speed of the center of pressure displacement in the antero-posterior directions; MSml: mean speed of the center of pressure displacement in the medial-lateral directions; SOT: Sensory Organization Test.
Risk of bias assessment.
| Study | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Total score |
|---|---|---|---|---|---|---|---|---|---|
| Study design | Participants representativeness | Equivalence of comparison groups | |||||||
| Moraes (2021) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 7/8 |
| Moraes (2020) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 7/8 |
| Muñoz-Lasa (2019) | Yes | Yes | Yes | No | No | Yes | Yes | No | 5/8 |
| Vermöhlen (2017) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 7/8 |
| Frevel (2015) | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 7/8 |
| Lindroth (2015) | Yes | No | Yes | No | No | Yes | No | No | 3/8 |
| Menezes (2013) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | 6/8 |
| Muñoz-Lasa (2011) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | 6/8 |
| Silkwood-Sherer (2007) | Yes | Yes | Yes | No | No | Yes | Yes | Yes | 6/8 |
| Hammer (2005) | Yes | No | Yes | No | No | Yes | No | No | 3/8 |
Item 1: cohort. Item 2: control or comparison group. Item 3: pre-/postintervention data. Item 4: random assignment of participants to the intervention. Item 5: random selection of participants for assessment. Item 6: follow-up rate of 80% or more. Item 7: comparison groups equivalent on sociodemographics. Item 8: comparison groups equivalent at baseline on outcome measures.